▟ Vinebot intrinsic value, daily

← back

GILD Gilead Sciences

pharma · valued with opus medium conviction · deep-dived 2026-11-13

HOLD
Intrinsic value$93.08
Price (at call)$167.95
Margin of safety -44.6%
vs market (rating basis) -15.8%

Long-acting HIV extends a cash machine's runway; value hinges on M&A discipline, not the IPR&D-distorted GAAP loss.

The story

Gilead is a mature, cash-rich HIV franchise (Biktarvy, plus long-acting lenacapavir for PrEP and treatment) that funds a mixed oncology and liver portfolio and frequent acquisitions. The HIV moat comes from switching costs and a long-acting pipeline that pushes patent risk into the late 2030s. Growth is mid-single-digit, and the company is in the mature-but-durable stage of its life cycle. The negative TTM GAAP margin comes from acquired IPR&D charges, not deteriorating core economics.

Growth and terminal assumptions are unchanged; TTM revenue up 5.3% confirms about 6%. I made three material moves. Sales-to-capital rises from 0.62 to 0.85 because lenacapavir growth is organic and the 0.65 historical figure is inflated by acquisition goodwill. Horizon goes from 8 to 10 years because long-acting HIV extends franchise durability. Failure probability drops to 0.02 given $31B of revenue and investment-grade cash flows. The prior value of $71 against a $151 to $168 price implied a gap of over 100% that the facts no longer support.

Value drivers

Revenue growth (Y1)6.0%
Terminal growth3.5%
Forecast horizon10y
Target operating margin37.0%
Years to target margin3
Sales-to-capital0.85
Beta0.90
Failure probability2.0%
Cost of capital (WACC)8.8%
Terminal WACC9.2%

Valuation bridge

PV of explicit FCFF58.27B
PV of terminal value76.83B
Equity value115.45B
÷ shares → per share$93.08

Projected free cash flow to the firm

YrRevenueGrowthMarginNOPATReinvestFCFFPV
1 32.85B 6.0% 9.1% 2.58B 2.19B 397.55M 365.44M
2 34.73B 5.7% 23.0% 6.95B 2.21B 4.74B 4.00B
3 36.62B 5.4% 37.0% 11.77B 2.22B 9.55B 7.41B
4 38.51B 5.2% 37.0% 12.38B 2.23B 10.15B 7.25B
5 40.39B 4.9% 37.0% 12.98B 2.21B 10.77B 7.07B
6 42.25B 4.6% 37.0% 13.58B 2.19B 11.39B 6.87B
7 44.08B 4.3% 37.0% 14.17B 2.15B 12.02B 6.66B
8 45.87B 4.1% 37.0% 14.74B 2.10B 12.64B 6.44B
9 47.61B 3.8% 37.0% 15.30B 2.04B 13.26B 6.21B
10 49.27B 3.5% 37.0% 15.84B 1.96B 13.88B 5.98B

Key risks

  • Large IPR&D and M&A charges keep destroying value (TTM net loss of $3.9B)
  • IRA price negotiation and Medicare Part D redesign compress HIV net pricing
  • Oncology (Trodelvy, cell therapy) underdelivers, leaving the company dependent on HIV

Catalysts

  • Yeztugo (lenacapavir PrEP) uptake and payer coverage ramp
  • Once-weekly and twice-yearly HIV treatment combination readouts

History

DatePriceIntrinsicMoSRating
2026-11-13$167.95 $93.08 -44.6% HOLD
2026-10-12$151.17 $71.12 -53.0% HOLD
2026-09-08$151.00 $77.01 -49.0% HOLD
2026-08-06$131.76 $98.42 -25.3% BUY
2026-07-03$131.27 $102.59 -21.8% BUY
2026-06-23$125.05 $103.77 -17.0% STRONG BUY